Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
Heinzerling L, Urbanek M, Funk J, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89:1835-44.
Oct 15, 2000
Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
Oct 15, 2000
Cancer 2000; 89:1835-44
Heinzerling Lucie, Urbanek M, Funk J O, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R
more
